BRAF V600E mutation-specific antibody: A review
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 2×
“exclusive in many of these tumors, suggesting that they have a similar tumorigenic effect.(1,3,5,6)”
BackgroundImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904 · cited 5×
“Anti-EGFR therapy with agents such as cetuximab has become standard treatment for patients with advanced CRC.72 While results are conflicting, there is some indication that BRAF mutation may correlate with resistance to the anti-EGFR therapy.73 Thus, identification of a BRAF mutation is an established clinical tool to…”
BackgroundInfluentialHigh frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730 · cited 1×
“In melanoma, BRAF mutation seems to be an early event since many nevi harbor BRAF mutations.(2) While BRAF mutations in primary melanomas have not been found to impact disease-free or overall survival, there is some indication that BRAF mutations in metastatic melanoma impart a decreased survival rate.”
BackgroundWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“While results are conflicting, there is some indication that BRAF mutation may correlate with resistance to the anti-EGFR therapy.(73) Thus, identification of a BRAF mutation is an established clinical tool to exclude Lynch syndrome, has prognostic value in metastatic CRCs, and may be used to guide treatment decisions.”
BackgroundRAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 1×
“exclusive in many of these tumors, suggesting that they have a similar tumorigenic effect.(1,3,5,6)”
BackgroundBauer, J., Büttner, P., Murali, R., Okamoto, I., Kolaitis, N. A., Landi, M. T., Scolyer, R. A., & Bastian, B. C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00837.x · Cited by 211 · cited 1×
“, acral and mucosal melanomas) is low.(23,24) In melanoma, BRAF mutation seems to be an early event since many nevi harbor BRAF mutations.”
BackgroundToon, C. W., Walsh, M. D., Chou, A., Capper, D., Clarkson, A., Sioson, L., Clarke, S., Mead, S., Walters, R. J., Clendenning, M., et al. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31828f233d · Cited by 136 · cited 3×
“Study Tumor # of cases Antibody Sensitivity Specificity Boursault et al.22 Melanoma 230 VE1 (Spring Bio) 97% 100% Busam et al.31 Melanoma 51 VE1 hybridoma 100% 100% Capper et al.21 Melanoma 47 VE1 hybridoma 100% 100% Chen et al.32 Melanoma 38 V600E (NewEast Bio) 100% 93% Colomba et al.33 Melanoma 111 VE1 hybridoma 100…”
Result
Cited by
Hugdahl, E., Kalvenes, M. B., Puntervoll, H. E., Ladstein, R. G., & Akslen, L. A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.44 · Cited by 75
“Reported sensitivities range from 72% to 100%, and specificities range from 47% to 100% (Long et al, 2013; Ehsani et al, 2014; Liu et al, 2014; Thiel et al, 2014; Ritterhouse and Barletta, 2015).”
BackgroundPrecise definition of PTEN C-terminal epitopes and its implications in clinical oncology
Mingo, J., Luna, S., Gaafar, A., Nunes-Xavier, C. E., Torices, L., Mosteiro, L., Ruiz, R., Guerra, I., Llarena, R., Angulo, J. C., et al. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0083-4 · Cited by 22
Assessing variant effect predictors and disease mechanisms in intrinsically disordered proteins
Fawzy, M., & Marsh, J. A. (2025) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1013400 · Cited by 18
“The canonical oncogenic BRAF p.Val600Glu mutation [37,38] occurs in a region predicted to be disordered in our pipeline and activates the MAPK pathway by mimicking phosphorylation.”
Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations
Wang, W., Lian, B., Xu, C., Wang, Q., Li, Z., Zheng, N., Liu, A., Yu, J., Zhong, W., Wang, Z., et al. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100661 · Cited by 14
BRAFV600E mutation promoted the growth and chemoresistance of colorectal cancer.
(2023) · PubMed Central · Cited by 6
Metadata
- Authors
- Ritterhouse, L. L., & Barletta, J. A.
- Venue
- Seminars in Diagnostic Pathology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 32
- Issue
- 5
- Pages
- 400-408
- ISSN
- 0740-2570 (ISSN-L)
- OpenAlex
- W2037458776
- Cited by
- 172
- References
- 10
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.